HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Extract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rudofsky, G. Articles by Hamann, A. Search for Related Content PubMed Articles by Rudofsky, G., Jr. Articles by Hamann, A. Social Bookmarking                What's this?

Comment on: Lin et al. (2007) SUMO4 M55V Variant Is Associated With Diabetic Nephropathy in Type 2 Diabetes: Diabetes 56:1177–1180

From the Division of Endocrinology and Metabolism, Department of Medicine, University of Heidelberg, Heidelberg, Germany

Address correspondence to Andreas Hamann, MD, Division of Endocrinology and Metabolism, Department of Medicine, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany. E-mail: andreas_hamann{at}med.uni-heidelberg.de

Lin et al. (1) have recently reported a positive association of the SUMO4 M55V variant with diabetic nephropathy in an Asian cohort of 430 patients with type 2 diabetes. The authors found a strong association of the G allele with an increased risk for diabetic nephropathy.

Thus far, little is known about the physiologic role of the recently discovered posttranslational modifier SUMO4. One of the putative substrates of SUMO4 is the inhibitor B (IB), which negatively regulates transcriptional activity of the proinflammatory transcription factor nuclearfactor-B (NF-B) (2). SUMOylation seems to stabilize I-B resulting in a reduced activation of NF-B. Since excessive NF-B activation is supposed to promote micro- and macrovascular disease (2,3) SUMOylation of IB might modulate the development of late diabetes complications.

In contrast to Lin et al., we report no association of the SUMO4 M55V variant with diabetic nephropathy in 752 Caucasian patients with type 1 and type 2 diabetes (n = 237 and 515, respectively). The characterization of the study population was previously described in detail (4). To increase power, subjects with homozygous and heterozygous genotypes were combined for statistical analysis. No association was detected, either when all 752 diabetic patients were analyzed together (GG and GA, 32.6%; AA, 36.6%; P = 0.36) or when a separate analysis of patients with type 1 (GG and GA, 22.2%; AA, 19.2%; P = 0.70) and type 2 (GG and GA, 37.2%; AA, 43.9%; P = 0.20) diabetes was performed.

These differences might be explained by the ethnical background of the studied cohorts, e.g., Asian and Caucasian population, and thus demand further studies in different ethnic groups to clarify the effect of the SUMO4 M55V variant in diabetic nephropathy.

Received for publication February 19, 2007 and accepted in revised form February 20, 2007

REFERENCES

1. Lin HY, Wang CL, Hsiao PJ, Yung-Chuan L, Chen SY, Lin KD, Hsin SC, Hsieh MC, Shin SJ: SUMO4 M55V variant is associated with diabetic nephropathy in type 2 diabetes. Diabetes 56:1177–1180, 2007[Abstract/Free Full Text]
2. Guo D, Li M, Zhang Y, Yang P, Eckenrode S, Hopkins D, Zheng W, Purohit S, Podolsky RH, Muir A, Wang J, Dong Z, Brusko T, Atkinson M, Pozzilli P, Zeidler A, Raffel LJ, Jacob CO, Park Y, Serrano-Rios M, Larrad MT, Zhang Z, Garchon HJ, Bach JF, Rotter JI, She JX, Wang CY: A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet 36:837–841, 2004[Medline]
3. Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R, Nawroth PP: The role of oxidative stress and NF-kappaB activation in late diabetic complications. Biofactors 10:157–167, 1999[Medline]
4. Rudofsky G Jr, Schlimme M, Schlotterer A, von Eynatten M, Reismann P, Tafel J, Grafe I, Morcos M, Nawroth P, Bierhaus A, Hamann A: No association of the 94T/G polymorphism in the adiponectin gene with diabetic complications. Diabetes Obes Metab 7:455–459, 2005[Medline]

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				S.-J. Shin, H.-Y. Lin, C.-L. Wang, P.-J. Hsiao, and K.-D. Lin Response to Comment on: Lin et al. (2007) SUMO4 M55V Variant Is Associated With Diabetic Nephropathy in Type 2 Diabetes: Diabetes 56:1177 1180 Diabetes, August 1, 2007; 56(8): e12 - e13. [Full Text] [PDF]

This Article Extract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rudofsky, G. Articles by Hamann, A. Search for Related Content PubMed Articles by Rudofsky, G., Jr. Articles by Hamann, A. Social Bookmarking                What's this?